Targeted Agent & Profiling Utilization Registry Study
About the TAPUR Study
In oncology, it’s becoming more common to conduct tumor genomic profiling—particularly for patients who have advanced cancer or patients who have exhausted all standard treatment options—to determine whether or not the results might suggest a previously unrecognized therapy option. Although not always the case, it may be reasonable to expect that a targeted agent that is effective in patients selected according to a biomarker (i.e., genomic alteration) in one type of cancer may be effective for patients with another type of cancer that harbors the same genomic alteration. Thus, genomic profiling might reveal therapy options for patients such as treatment with an investigational agent in a clinical trial or use of a targeted therapy drug that has been approved by FDA for a different cancer.
However, it’s often difficult for patients to get access to and reimbursement for anti-cancer agents used off-label. And, even if an oncologist can get access to a drug and treat the patient, the larger medical community has no way to learn whether that particular drug worked in that patient with those particular characteristics. Current prescribing practices don’t capture the outcomes of patients who receive therapies off-label.
The Targeted Agent and Profiling Utilization Registry (TAPUR™) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
The study provides FDA-approved targeted therapies contributed by collaborating pharmaceutical companies, catalogs the choice of genomic profiling test by clinical oncologists, and aims to identify potential signals of drug activity.
ASCO plans to make results available to all participants involved in the study. In addition, ASCO plans to report study results through existing mechanisms, i.e., scientific meetings and peer-reviewed publications.
TAPUR aims to
- Collect data on clinical outcomes to learn about new uses of these drugs outside of indications approved by the U.S. Food and Drug Administration
- Learn from the real-world practice of prescribing targeted therapies to patients whose tumors harbor a genomic variant known to be a drug target
- Educate oncologists about the implementation of precision medicine in clinical practice
- Catalog the choice of genomic profiling test by clinical oncologists and learn about the utility of registry data to develop hypotheses for additional clinical trials
Participants: Access to targeted study drugs matched to the genomic profiles of their cancers
Physicians: Assistance interpreting genomic results and identifying potential treatment options
Cancer Community: New uses of targeted anticancer drugs for patients who have exhausted standard options
Drug Manufacturers: Insights on new uses of existing drugs
Regulatory Authorities: Insights about side effects and treatment outcomes from use of approved drugs in other cancers
The Membership Directory is your go-to tool for finding and interacting with other members. Designed to keep you in touch with like-minded colleagues, the Membership Directory app enables you to build your professional network, connect with colleagues at meetings and easily provide other members’ information to patients seeking a referral. Using the app, members can search by name, organization, specialty and/or certification.
With new treatments coming out seemingly daily and limited time for learning, it can be hard to stay on top of the latest in oncology. So when you do have the time, you want the resources you utilize to meet your own learning style. The ASCO Personalized Learning Dashboard helps you to sift through all of the information out there and find content recommendations tailored to your media preferences.